Preliminary Clinical Data Highlights Potential to Expand Addressable Market to include Angle Closure Glaucoma

California, USA, 25 October 2023 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary canaloplasty devices – *iTrack™ and iTrack™ Advance* – were featured as part of the scientific program of the annual conference of Royal Australian and New Zealand College of Ophthalmologists (RANZCO) held in Perth, Australia, 20-23 October 2023.

Australian eye surgeon Nathan Kerr BHB, MBChB, MD, FRANZCO of Eye Surgery Associates, who is also Consultant Ophthalmologist at the Royal Victorian Eye and Ear Hospital and Principal Investigator (Glaucoma) at the Centre for Eye Research Australia (CERA), presented on the topic: "*Multicenter iTrack Canaloplasty Data Registry – Outcomes of Ab-Interno Canaloplasty Across Different Glaucoma Types and Severity*".

The presentation addressed the 12-month clinical outcomes of 82 of the 367 glaucoma patients who underwent canaloplasty treatment with the iTrack™ or iTrack™ Advance device via the iTrack™ Global Data Registry.

The iTrack™ Global Data Registry is incorporated in the global *International Glaucoma Surgery Registry (IGSR)*, an observational, non-interventional study of patients undergoing laser or surgical treatment for glaucoma. Established five years ago, the IGSR already counts more 7000 procedures in 63 countries and is the official registry partner of the European Glaucoma Society (EGS). The IGSR was founded by Prof. Keith Barton, MD, FRCO, FRCS (United Kingdom) and Dr. Nathan Kerr, BHB, MBChB, MD, FRANZCO (Australia).

While the data presented at RANZCO has not yet undergone peer review, the Company is optimistic about the potential role of this data in supporting an expansion in the total addressable market for its iTrack™ and iTrack™ Advance canaloplasty devices.

"More patients will need to reach a minimum 12-month follow-up before we can draw any statistically meaningful conclusions from the data, but this preliminary analysis suggests

that our iTrack™ and iTrack™ Advance devices may play an important role in the treatment of angle closure glaucoma," commented Nova Eye Chief Commercial Officer, Kate Hunt.

"Angle closure glaucoma is not currently indicated for treatment by MIGS devices and yet accounts for most glaucoma cases throughout Asia. The global population of people with angle closure glaucoma is estimated at 30 million.[1] This data highlights the potential to significantly expand the available market for iTrack™ and iTrack™ Advance to include angle closure glaucoma."

1. Market Scope "*2023 Glaucoma Surgical Device Market Report"*

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next,

viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

The iTrack™ Advance canaloplasty device has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

For additional information about the *iTrack™ Advance*, including safety information, please visit: https://itrack-advance.com/us

For media enquiries, please contact:
Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com
Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu